Commitment to Women’s Health

This strategic appointment underscores LifeMD’s ambition to enhance one of the most comprehensive women’s health offerings in the nation. Dr. Scott will play a vital role in promoting awareness of critical women’s health topics, including:

• Perimenopause and menopause
• Hormonal balance
• Bone density
• Metabolism
• Long-term wellness

Features of LifeMD’s Virtual Women’s Health Program

LifeMD’s women’s health program offers an array of services designed to cater to the unique needs of women across different life stages:

• Virtual consultations incorporating clinical expertise and personalized treatment options, including hormone therapy.
• A holistic approach with tiered subscriptions covering lab access, mail-order prescriptions, and dietitian services.
• LifeMD+ membership providing 24/7 access to urgent and primary care, prescription renewals, and a marketplace of clinically validated wellness products.

Expertise and Vision

Jessica Friedeman, Chief Marketing and Product Officer at LifeMD, expressed enthusiasm about Dr. Scott’s appointment: “We are honored to welcome Dr. Scott as an ambassador. Her extensive knowledge and advocacy align seamlessly with our mission to improve women’s healthcare throughout their lives.”

Dr. Scott, a board-certified obstetrician-gynecologist and menopause specialist, brings over 25 years of clinical and educational experience. She is notable for her research-based strategies regarding hormonal balance and has been featured in prominent media outlets such as Women’s Health and Newsweek.

“Serving as an ambassador for LifeMD’s women’s health program is a privilege,” remarked Dr. Scott. “It addresses the confusion many women face, particularly regarding menopause and hormonal issues. This program empowers women to make informed health decisions.”

Addressing Underserved Health Areas

Despite increasing awareness, women’s health continues to be a largely neglected sector. Critical issues such as menopause and osteoporosis remain significantly underdiagnosed:

• Only 25% of women pursue treatment for menopause-related symptoms.
• Women constitute 80% of osteoporosis cases, yet over two-thirds are undiagnosed.

Research by BCG indicates that these areas alone represent a potential market opportunity of $60-70 billion by 2030, showcasing significant growth potential.